Metagenomi Therapeutics Inc MGX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-02-09 |
| Shares Out. | 37,650,000 |
| Website | metagenomi.co/ ↗ |
| Phone | 15108714880 |
| Employees | 118 |
| Revenue | $1.2M |
| Gross Profit | $1.2M |
| Net Income | -$23.1M |
| Free Cash Flow | -$87.5M |
| Total Assets | $197.0M |
| Total Liabilities | $59.2M |
| Equity | $137.8M |
About Metagenomi Therapeutics Inc
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Metagenomi Therapeutics Inc is a publicly traded company under the ticker symbol MGX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)